secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2021-10-08T23:59:59+00:00
Accession:  0001193125-21-295465
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vanda's Corporate Affairs & Communications Officer Aranthan Jones II resigns, effective Oct 26, 2021
--------------------------------------------------------------------------------

- Aranthan 'AJ' Jones II resigns as Corporate Affairs and Communications Officer, effective October 26, 2021.
- Jones is leaving to join a U.S.-based publicly traded company outside the biopharmaceutical sector.
- No successor has been announced at this time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312521295465/0001193125-21-295465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312521295465/d238861d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-295465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer